Abeona Therapeutics beats consensus with Q3 loss of $0.08 per share
ABEO Abeona Therapeutics Inc
$2.45 -3.35%
View chart & analysis → 
- 1Abeona Therapeutics' Q3 loss of $0.08 per share beat the Q3 consensus of -$0.14 by 42.9%.
- 2Abeona Therapeutics' Q3 ZEVASKYN net revenue of $13.49 million missed the Q3 consensus of $18.07 million by 25.3%.
- 3Abeona Therapeutics acquired APT-1011 (currently ABO-801).
So what's the key point?
Abeona Therapeutics reported a smaller loss of $0.08 per share in the third quarter than expected. While revenue was lower than analyst estimates, the company acquired a new drug.
Source Nasdaq +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.